# Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

> **NCT04725994** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Idience Co., Ltd.** · enrollment: 87 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** IDX-1197+XELOX
- **DRUG:** IDX-1197+Irinotecan

## Key facts

- **NCT ID:** NCT04725994
- **Lead sponsor:** Idience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-28
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725994, "Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04725994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*